{"id":52451,"date":"2025-08-30T03:08:40","date_gmt":"2025-08-30T07:08:40","guid":{"rendered":"https:\/\/stockmarketwatch.com\/stock-market-news\/california-softens-oil-stance-leqembi-gains-self-injection-approval\/52451\/"},"modified":"2025-08-30T03:08:40","modified_gmt":"2025-08-30T07:08:40","slug":"california-softens-oil-stance-leqembi-gains-self-injection-approval","status":"publish","type":"post","link":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/california-softens-oil-stance-leqembi-gains-self-injection-approval\/52451\/","title":{"rendered":"California Softens Oil Stance, Leqembi Gains Self-Injection Approval"},"content":{"rendered":"<h2>Key Takeaways<\/h2>\n<ul>\n<li><strong>California&#39;s Energy Commission has postponed the implementation of a controversial profit cap on oil refiners until 2030, signaling a significant shift in the state&#39;s regulatory approach amidst concerns over fuel supply stability and rising gasoline prices.<\/strong><\/li>\n<li><strong>Eisai (<a href=\"\/stock\/ESALY\">ESALY<\/a>) and Biogen (<a href=\"\/stock\/BIIB\">BIIB<\/a>) have secured U.S. regulatory approval for a new self-injected, subcutaneous form of their Alzheimer&#39;s drug, Leqembi (<a href=\"\/stock\/LEQEMBI\">LEQEMBI<\/a>), promising greater convenience for patients and potentially expanding treatment accessibility.<\/strong><\/li>\n<li><strong>The delay in California&#39;s profit cap enforcement is a win for the oil and gas industry, providing &quot;certainty&quot; for investments but drawing criticism from consumer advocates who fear continued price spikes.<\/strong><\/li>\n<li><strong>The new self-injectable Leqembi (<a href=\"\/stock\/LEQEMBI\">LEQEMBI<\/a>) formulation, with a PDUFA action date of August 31, 2025, is expected to simplify long-term treatment regimens, reducing the need for frequent hospital or infusion center visits.<\/strong><\/li>\n<\/ul>\n<p>California&#39;s energy regulators have announced a significant policy reversal, delaying the enforcement of a profit cap on oil refiners until <strong>2030<\/strong>. This move by the <strong>California Energy Commission (CEC)<\/strong> represents a notable softening of the state&#39;s stance toward the oil and gas industry, which has been under intense scrutiny regarding high gasoline prices. The decision comes amid concerns that refinery closures, which have reduced California&#39;s refining capacity by approximately <strong>18%<\/strong>, could exacerbate fuel supply issues and lead to even higher prices at the pump.<\/p>\n<p>In separate but equally impactful news, pharmaceutical giants <strong>Eisai Co. Ltd. (<a href=\"\/stock\/ESALY\">ESALY<\/a>)<\/strong> and <strong>Biogen Inc. (<a href=\"\/stock\/BIIB\">BIIB<\/a>)<\/strong> have received U.S. regulatory approval for a new self-injected version of their pioneering Alzheimer\u2019s drug, <strong>Leqembi (<a href=\"\/stock\/LEQEMBI\">LEQEMBI<\/a>)<\/strong>. This development is poised to transform the treatment experience for patients with early Alzheimer&#39;s disease, offering a more convenient and accessible administration method.<\/p>\n<h2>California&#39;s Energy Policy Shift<\/h2>\n<p>The <strong>California Energy Commission&#39;s<\/strong> decision to postpone the refinery profit cap, originally part of Governor Gavin Newsom&#39;s 2023 law aimed at penalizing excessive oil company profits, is a direct response to the state&#39;s ongoing struggle with the highest gasoline prices in the nation. Officials cited the need to stabilize fuel supply, particularly after two refineries announced plans to close, impacting about one-fifth of the state&#39;s crude-processing capacity. Experts had warned that imposing penalties could discourage crucial investments in oil production and further escalate fuel costs.<\/p>\n<p><strong>Siva Gunda<\/strong>, Vice Chair of the <strong>California Energy Commission<\/strong>, indicated that the profit cap could act as a &quot;deterrent&quot; to refiners investing in the state, underscoring the commission&#39;s desire to boost gasoline supply. While the oil industry has welcomed the delay, calling it a source of &quot;certainty,&quot; consumer advocacy groups, such as <strong>Consumer Watchdog<\/strong>, have criticized the move as a &quot;giveaway to the industry&quot; that could lead to increased price volatility for consumers.<\/p>\n<h2>Leqembi&#39;s Game-Changing Self-Injection Approval<\/h2>\n<p>The <strong>U.S. Food and Drug Administration (FDA)<\/strong> has accepted <strong>Eisai&#39;s (<a href=\"\/stock\/ESALY\">ESALY<\/a>)<\/strong> Biologics License Application (BLA) for a subcutaneous autoinjector of <strong>Leqembi (<a href=\"\/stock\/LEQEMBI\">LEQEMBI<\/a>)<\/strong>, with a Prescription Drug User Fee Act (PDUFA) action date set for <strong>August 31, 2025<\/strong>. This approval means patients with mild cognitive impairment or mild dementia due to Alzheimer&#39;s disease will soon have the option of weekly at-home injections, significantly reducing the burden of bi-weekly intravenous infusions at hospitals or specialized infusion centers.<\/p>\n<p>This new self-administered formulation is expected to maintain the drug&#39;s clinical and biomarker benefits, with studies showing the subcutaneous form cleared <strong>14% more amyloid plaque<\/strong> than the infused version in certain patients. The convenience offered by the autoinjector could lead to higher patient adherence and broader access to treatment. This follows the <strong>FDA&#39;s<\/strong> earlier approval in January 2025 for a once-every-four-weeks intravenous maintenance dosing of <strong>Leqembi (<a href=\"\/stock\/LEQEMBI\">LEQEMBI<\/a>)<\/strong>, further simplifying the treatment pathway after an initial bi-weekly phase. Analysts project <strong>Leqembi (<a href=\"\/stock\/LEQEMBI\">LEQEMBI<\/a>)<\/strong> to generate <strong>$5.3 billion<\/strong> in sales for <strong>Eisai (<a href=\"\/stock\/ESALY\">ESALY<\/a>)<\/strong> and <strong>Biogen (<a href=\"\/stock\/BIIB\">BIIB<\/a>)<\/strong> by 2030, highlighting its market potential.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Key Takeaways California&#39;s Energy Commission has postponed the implementation of a controversial profit cap on oil refiners until 2030, signaling [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":50383,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"rank_math_schema_Article":[],"rank_math_focus_keyword":[],"rank_math_description":[],"financial_data_references":[],"stock_symbols_mentioned":[],"footnotes":""},"categories":[5012],"tags":[9626,9627,5030,9628,5227,9629,5362,9630,5833,9631,7013,9632,8412,9329,9624,9625],"class_list":["post-52451","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-breaking-news","tag-alzheimers-disease","tag-eisai","tag-energy","tag-esaly-stock-esaly","tag-healthcare","tag-biib-stock-biib","tag-oil-gas","tag-cec","tag-fda","tag-bla","tag-biogen","tag-pdufa","tag-pharmaceutical","tag-leqembi","tag-california-energy-commission","tag-refinery-profits"],"_links":{"self":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts\/52451","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/comments?post=52451"}],"version-history":[{"count":0,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts\/52451\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/media\/50383"}],"wp:attachment":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/media?parent=52451"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/categories?post=52451"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/tags?post=52451"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}